<div>
  <ul>
    <li>
      <p>
        BigHat Biosciences has teamed up with Janssen Biotech in a strategic collaboration to develop novel therapeutics using the companies' combined expertise in drug discovery and AI/ML. The terms and financial details of the partnership have not been disclosed.
      </p>
    </li>
    <li>
      <p>
        This collaboration targets the discovery and verification of potential proteins, as well as simplifying the design of antibodies and other treatments for a range of conditions, from chronic illnesses to life-threatening diseases. It hopes to achieve this by using BigHat's proprietary AI/ML-powered platform, Milliner, and Janssen&rsquo;s drug development and data science expertise.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.bighatbio.com/news/bighat-biosciences-enters-into-strategic-collaboration-to-leverage-machine-learning-in-antibody-discovery-design">
      Press release
    </a>
  </p>
</div>


AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 <p>BigHat Biosciences and Janssen Biotech have entered a joint venture to develop novel therapeutic solutions. The two companies plan to combine their respective proficiency in drug discovery and artificial intelligence/machine learning (AI/ML) for this project. The specifics and financial conditions surrounding the partnership have yet to be revealed.</p>
 <p>Dedicated to spotting and confirming potential proteins, the collaboration seeks to simplify the creation of antibodies and other forms of treatment for various health ailments. The scope of these conditions range from chronic diseases to those that are life-threatening. BigHat's distinctive AI/ML-fueled platform, known as Milliner, and Janssen's proficiency in drug development and data science will be instrumental in achieving these objectives.</p>
 
</div>

BigHat Biosciences collaborates with Janssen Biotech for next-gen protein therapeutics design

<div>
 <p>Odyssey Therapeutics and Janssen Pharmaceuticals have formed a partnership to investigate the development of precise drug treatments against certain therapeutic targets using innovative technologies and small-molecule medicines. The collaboration is facilitated by Johnson &amp; Johnson Innovation.</p>
 <p>The combined efforts tap into both partners' expertise in AI, ML, computational chemistry, and drug discovery with the objective of finding solutions to tackle challenging drug targets. The goal of this partnership is to expedite the drug discovery and development process using shared tools and data. According to the agreement, Odyssey will team up with Johnson &amp; Johnson's experts and data scientists to use AI and ML in discovering and optimizing small-molecule therapeutics. Odyssey will also receive an upfront payment, and there is the potential for milestone payments and future royalties.</p>
 
</div>

Odyssey Therapeutics partners with Janssen Pharmaceuticals to progress AI-powered small-molecule drug discovery

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>
 <p>Odyssey Therapeutics is collaborating with Janssen Pharmaceuticals, through a partnership enabled by Johnson &amp; Johnson Innovation, to develop small-molecule medicines for precise targeted treatments. They are using state-of-the-art technologies to achieve this goal.</p>
 <p>The partners will employ AI, ML, computational chemistry, and drug discovery know-how in their joint effort to address challenging drug targets. Mutual tools and data will be used to speed up drug discovery and development. According to the agreement, Odyssey will liaise with Johnson &amp; Johnson's experts and data scientists in using AI and ML to discover and optimize small-molecule therapeutics. Odyssey will receive an initial payment, with the prospect of further milestone payments and royalties in the future.</p>
</div>

<div>
 <p>Janssen Pharmaceuticals has partnered with Predicine to develop a urine-based CDx tool for identifying bladder cancer patients who may benefit from targeted therapies. The financial details remain undisclosed. The test by California-based Predicine uses next-generation sequencing to detect alterations in cancer-relevant genes. PredicineCare, a blood and urine cfDNA test covering 152 actionable genes, received a CE-IVD mark and US FDA breakthrough device designation in August 2022. </p>
</div>

Janssen Pharmaceuticals partnered with Predicine to develop urine-based test as CDx tool to focusing on bladder cancer

<div>
 <p>Genetic testing firm BillionToOne has partnered with Janssen R&amp;D, a Johnson &amp; Johnson company, to conduct a global clinical trial for severe hemolytic disease. They will use BillionToOne's UNITY Fetal Antigen Clinical Trial Assay (CTA) to select participants for a critical Phase III trial. The partnership might result in a non-invasive prenatal test that detects blood type incompatibility between a pregnant person and a fetus. The assay is expected to receive global regulatory approval as the trial advances and is aiming to be implemented across the US, European Union, and other select countries.</p>
</div>

BillionToOne collaborates with Janssen to perform clinical trial in hemolytic disease

Novel therapies to reboot cells and organs

Cell & Gene Therapy

<div>
 
 <p>Janssen Pharmaceuticals, a sector of Johnson &amp; Johnson's (J&amp;J), has bought an X-linked retinitis pigmentosa (XLRP) gene therapy, botareti­gene sparopar­vovec, from MeiraGTx. The purchase was originally under the 2019 <a href="https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-enters-strategic-collaboration-janssen-develop-and"> partnership </a> between MeiraGTx and Janssen Pharmaceuticals. Bota-vec addresses XLRP, a hereditary retinal disease that leads to vision impairment, and has gone through Phase I/II trials.</p>
 <p>Janssen will pay an upfront fee of USD 130 million and a further USD 285 million upon successful commercial sales in the US and EU. The deal strengthens MeiraGTx's financial position, prolonging its cash runway to mid-2026. The funds will be used to enhance Xerostomia and Parkinson's disease clinical programs and manufacturing capabilities.</p>
  
</div>

All Updates

BigHat Biosciences collaborates with Janssen Biotech for next-gen protein therapeutics design

Odyssey Therapeutics partners with Janssen Pharmaceuticals to progress AI-powered small-molecule drug discovery

Odyssey Therapeutics partners with Janssen Pharmaceuticals to progress AI-powered small-molecule drug discovery

Janssen Pharmaceuticals partnered with Predicine to develop urine-based test as CDx tool to focusing on bladder cancer

BillionToOne collaborates with Janssen to perform clinical trial in hemolytic disease

Janssen Pharmaceuticals acquires XLRP Gene Therapy from MeiraGTx

Diatech Pharmacogenetics partners with Janssen Pharmaceutica to Advance Precision Testing in Oncology

Thermo Fisher Scientific receives FDA approval for use of Oncomine Dx assay with Janssen drug

AI Drug Discovery

BigHat Biosciences collaborates with Janssen Biotech for next-gen protein therapeutics design

Contact us